<DOC>
	<DOCNO>NCT02825212</DOCNO>
	<brief_summary>10 patient chronic genotype 1 HCV infection mix cryoglobulinemia treat Ledipasvir/Sofosbuvir 90mg/400 mg FDC daily 12 week ( naïve subject non-cirrhotic treatment experienced subject ) 24 week ( treatment experience subject cirrhosis ) . The researcher anticipate approximately 20 % subject may cirrhosis .</brief_summary>
	<brief_title>Efficacy All-Oral Anti-Viral Therapy Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia</brief_title>
	<detailed_description>The treatment extrahepatic disease manifestation HCV largely parallel hepatic disease . Interferon report efficacy MC even linkage syndrome HCV 1989 , successful combination therapy ribavirin find eliminate virus lead resolution immunologic abnormality associate extrahepatic disease . In addition , ~75 % HCV-associated indolent asymptomatic lymphoproliferative disease remit successful antiviral therapy . However , many instance , MC ( notably cutaneous vasculitis ) relapse recurrence virus , may occasionally persist even clearance . In particular , side effect Interferon alpha , include uncover frank autoimmune disease , theoretically may mitigate response extrahepatic disease treatment . Peg-interferon increase response rate MC , decrease duration treatment , side effect remain problematic . An alternative approach treatment MC use immunomodulatory agent . In particular , B-cell expansion peripheral blood lymphoid follicles liver prevalent amongst HCV-infected person provide rationale use depletion therapeutic strategy . Rituximab ( anti-CD20 ) monotherapy use mostly treatment failures/intolerance set NHL , yield response rate set involvement skin ( 73 % ) ; MPGN ( 70 % ) ; joint ( 53 % ) ; nerve ( 36 % ) . However , monoclonal antibody ( MAb ) potential form immune-complexes mixed cryoglobulin RF cause clinical vasculitis patient high cryocrits , may raise HCV RNA level rare patient , cause cytotoxicity . Following Rituximab Peg-IFN plus ribavirin achieve great 60 % complete response ( CR ) patient resistant combination treatment alone . Other approach include use Aldesleukin , inducer regulatory T-cell activity , MAbs target specific B-cell subset costimulatory signal molecule ( e.g . BAFF ) agent inhibit interaction HCV core antigen C1q cryoprecipitates via receptor globular domain C1q ( gC1qR ) . The development low molecular weight inhibitor non-structural protein ( NSPs ) elaborate HCV , particular 5A , 5B nucleoside non-nucleoside polymerase inhibitor , inhibitor 3/4A serine protease ; selectively inhibit HCV replication raise prospect `` all-oral '' treatment hepatic extrahepatic manifestation disease . However , use first generation direct-acting antiviral agent ( Telaprevir® Boceprevir® linear NS3/4A protease inhibitor ) limit frequent escape mutant , efficacy restrict genotype-1 , need retain protocol include PegIFN ribavirin , potential significant drug interaction , serious side effect . In trial combination therapy include Telaprevir® 13 patient MC , significant AEs , include asthenia ( 92 % ) , anemia ( 84 % ) , neutropenia bacterial infection ( 54 % ) . Approval uridine nucleoside analogue selectively inhibit HCV NS5B RNA-dependent RNA polymerase ( Sofosbuvir ) FDA late 2013 lead proof-of-concept trial combination all-oral therapy proven effective genotype 1 genotype , number regimen development . In particular , combination Sobosbuvir ( SOF ) Ledipasvir ( LDV ) report almost universal efficacy 12 week regimen genotype 1 , combination SOF Ribavirin ( RBV ) genotypes 2-6 24 week regimen . However , persistence cryoglobulinemia even viral clearance newer regimen also raise question whether long treatment regimen may appropriate set significant extrahepatic disease . Thus , time right initiate trial all-oral treatment rigorously evaluate effect extrahepatic disease , re-establish efficacy antiviral therapy halt direct indirect role HCV drive autoimmune disease lymphoproliferation . Using interferon-sparing regimen treat patient HCV-related cryoglobulinemia help answer question whether immunomodulating therapy play role eradicate cryoglobulins long-term , whether antiviral therapy alone adequate . If latter , appreciable morbidity mortality may save avoid treat potentially sick , often cirrhotic patient , immunomodulatory therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Cryoglobulinemia</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible participation study . 1 . Willing able provide write informed consent 2 . Male female , age ≥18 year 3 . HCV RNA ≥ 15 IU/mL Screening 4 . HCV genotype 1 5 . Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy 6 . Classification treatment naïve treatment experience : 1 . Treatment naïve define never expose approve experimental HCVspecific directacting antiviral agent prior treatment HCV interferon ribavirin DAAs ( except SOFcontaining regimen ) . 2 . Treatment experience defined prior treatment failure relapse regimen contain interferon either without RBV DAAs ( except SOFcontaining regimen ) complete least 8 week prior Baseline/Day 1 . The subject 's medical record must include sufficient detail prior virologic failure allow categorization prior response , either : 1 . NonResponder : Subject achieve undetectable HCV RNA level treatment , 2 . Relapse/Breakthrough : Subject achieve undetectable HCV RNA level treatment within 4 week end treatment achieve SVR . 7 . Cirrhosis determination ( approximately 20 % subject may cirrhosis ) a. Cirrhosis define one following : ) Any previous liver biopsy show cirrhosis ( e.g. , Metavir score = 4 Ishak score ≥5 ) ii ) FibroMeter® score &gt; 0.442 AST : platelet ratio index ( APRI ) &gt; 2 Screening iii ) Fibroscan result &gt; 12.5 kPa time prior screening . b . Absence cirrhosis define one following : ) Liver biopsy within 2 year Screening show absence cirrhosis ii ) FibroMeter® score &lt; 0.442 APRI ≤ 1 perform Screening iii ) Fibroscan result ≤12.5 kPa within 6 month Baseline/Day 1 Fibroscan result supersede FibroMeter® /APRI ; liver biopsy result supersede Fibrotest® /APRI Fibroscan result consider definitive . 8 . Liver imaging ( ultrasound , CT scan MRI ) within 6 month screen required patient cirrhosis exclude hepatocellular carcinoma ( HCC ) 9 . Presence MC vasculitis ( please see criteria note ) . 10 . Null partial response previous therapy MC , include corticosteroid , cytotoxic agent ( cyclophosphamide , azathioprine ) , hydroxychloroquine , methotrexate , mono combination therapy IFNα/PEGIFN ribavirin , and/or CD20 depletion Rituximab . . Patients ongoing treatment one drug describe inclusion unless significant DDI . 11 . Subjects follow laboratory parameter screen : 1 . ALT &lt; 10 x upper limit normal ( ULN ) 2 . AST &lt; 10 x ULN 3 . Adequate bone marrow function indicate hematologic parameter list and/or bone marrow cellularity &gt; 6070 % average age . i. WBC &gt; 1500 /uL ii.Platelets &gt; 50,000/uL ) Direct bilirubin &gt; 2 x ULN e ) INR &gt; 1.5 x ULN unless subject know hemophilia stable anticoagulant regimen affect INR 12 . Females childbearing potential must negative serum pregnancy test Screening negative urine pregnancy test Baseline/Day 1 prior treatment . 13 . Male subject female subject childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception . 14 . Lactating female must agree discontinue nursing study drug administer . 15 . Subject must generally good health , exception chronic HCV infection , determine Investigator . 16 . Subject must able comply dose instruction study drug administration able complete study schedule assessment . Note : Definition Mixed Cryoglobulinemia ( patient must meet one five overlap syndrome list presence coldprecipitable immune complex blood two different occasion . Clinical evidence cryoglobulinemia , overlap syndrome : 1 . Cutaneous vasculitis ( Raynaud 's phenomenon , purpura , skin ulcer , livedo , acrocyanosis ) 2 . Glomerulonephritis ( hypertension , hematuria , nephrotic syndrome ) 3 . Arthropathy ( arthralgia , arthritis ) 4 . Neuropathy ( peripheral and/or central nervous system , distal sensorimotor , mononeuritis multiplex ) 5 . Sicca syndrome ( xerostomia , xerophthalmia ) Other factor assess / record patient MC : 1 . Associated laboratory abnormality include : Positive HCV serology ( recombinant immunoblot assay ) , viral nucleic acid quantitation diagnostic HCV infection , reflex genotyping . Evidence glomerulonephritis , include active urinary sediment , hypoalbuminemia ( albumin &lt; 3gm/dL ) and/or significant proteinuria ( &gt; 300mg/day ) . Abnormal nerve conduction test . 2 . Pathologic evidence cryoglobulinemia include : Leukocytoclastic vasculitis . Membranoproliferative glomerulonephritis . Vasculopathy and/or mononuclear cell infiltrate sural nerve biopsy . Lip biopsy suggestive Sjogren 's syndrome . 3 . Laboratory evidence cryoglobulinemia include : Characterization cryoprecipitable material serum immunofixation , cryocrit , and/or quantitation protein . Associated immunological abnormality , depressed level complement , elevate titer rheumatoid factor , abnormal immunoglobulin quantitations , serum immunofixation carry serum and/or isolated cryoglobulins . 4 . Laboratory evidence Bcell clonality , include : IgMk determine immunofixation serum and/or cryoglobulin , kappa excess &gt; 2.65:1 Free Light Chain ( FLC ) assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cryoglobulinemia</keyword>
</DOC>